文献速递心脑血管急症重症综合管理与镇静镇痛

促红细胞生成素在创伤性脑损伤患者中的疗效与安全性:系统评价与荟萃分析

Efficacy and safety of erythropoietin in patients with traumatic brain injury: A systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2018-08-29
一句话结论荟萃分析提示,促红细胞生成素可能降低创伤性脑损伤后的死亡率,但未显著改善神经功能结局,也未增加深静脉血栓等并发症。

该研究为系统评价与荟萃分析,检索截至2017年1月5日的电子数据库,纳入6项随机对照临床试验、共1041例创伤性脑损伤患者,比较促红细胞生成素治疗组与未治疗组的结局。结果显示,促红细胞生成素显著降低死亡率(RR 0.68,95%CI 0.50-0.95,P=0.02),但未显著减少不良功能结局(RR 1.22,95%CI 0.82-1.81,P=0.33);深静脉血栓等并发症的发生率在两组间无显著差异(RR -0.02,95%CI -0.06-0.02,P=0.81)。作者结论认为,促红细胞生成素可能预防创伤性脑损伤后的死亡且不增加深静脉血栓等不良事件,但其改善神经功能结局的作用仍不明确,需进一步设计良好的随机对照试验验证。

要点

  • 在6项随机对照试验、共1041例创伤性脑损伤患者中,促红细胞生成素显著降低死亡率(RR 0.68,95%CI 0.50-0.95,P=0.02)。
  • 促红细胞生成素未显著减少不良功能结局(RR 1.22,95%CI 0.82-1.81,P=0.33)。
  • 促红细胞生成素组与对照组深静脉血栓等并发症发生率无显著差异(RR -0.02,95%CI -0.06-0.02,P=0.81)。
  • 作者认为促红细胞生成素可能预防创伤性脑损伤后的死亡且不增加深静脉血栓等不良事件。
  • 作者指出促红细胞生成素改善神经功能结局的作用仍不明确,需进一步设计良好的随机对照试验验证。

适用人群与场景

  • 创伤性脑损伤患者,纳入6项随机对照临床试验共1041例,比较促红细胞生成素治疗与未治疗者。

研究设计与关键结果

  • 研究类型为系统评价与荟萃分析,纳入6项随机对照临床试验,共1041例创伤性脑损伤患者,比较促红细胞生成素治疗组与未治疗组。
  • 促红细胞生成素显著降低死亡率(RR 0.68,95%CI 0.50-0.95,P=0.02)。
  • 促红细胞生成素未显著减少不良功能结局(RR 1.22,95%CI 0.82-1.81,P=0.33)。
  • 深静脉血栓等并发症发生率在两组间无显著差异(RR -0.02,95%CI -0.06-0.02,P=0.81)。

证据类型、等级与局限

  • 证据类型为系统评价与荟萃分析,纳入6项随机对照临床试验。
  • 局限:作者指出促红细胞生成素改善神经功能结局的作用仍不明确,需进一步设计良好的随机对照试验、采用改良方案并针对特定患者人群来阐明该问题并验证结果。

对床旁实践的改变

  • 作者认为,促红细胞生成素可能预防创伤性脑损伤后的死亡,且不增加深静脉血栓等不良事件。
  • 作者指出,促红细胞生成素在改善神经功能结局方面的作用仍不明确。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to evaluate the effects of erythropoietin (EPO) on mortality and neurological outcomes in patients with traumatic brain injury (TBI).

MATERIALS AND METHODS: Electronic databases of studies published up to January 5, 2017 were searched to retrieve relevant investigations comparing the outcomes of EPO-treated patients and untreated patients following TBI. We calculated the relative risk (RR) of mortality, neurologic outcomes, and deep vein thrombosis (DVT) with corresponding 95% confidence interval (CI) using meta-analysis.

RESULTS: Six randomized controlled clinical trials met the eligibility criteria. In total, 1041 patients were included among the studies. EPO was found to significantly reduce the occurrence of mortality (RR 0.68 [95% CI 0.50-0.95]; P = 0.02), but did not significantly reduce poor functional outcome (RR 1.22 [95% CI 0.82-1.81]; P = 0.33). There were no significant differences in the occurrence of complications, such as DVT, between the treatment groups (RR -0.02 [95% CI -0.06-0.02]; P = 0.81).

CONCLUSIONS: Results of the present meta-analysis suggest that the use of EPO may prevent death following TBI without causing adverse events, such as deep vein thrombosis. However, the role of EPO in improving neurological outcome(s) remains unclear. Further well-designed, randomized controlled trials using modified protocols and involving specific patient populations are required to clarify this issue, and to verify the findings.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Lee J, Cho Y, Choi KS, et al. Efficacy and safety of erythropoietin in patients with traumatic brain injury: A systematic review and meta-analysis. Am J Emerg Med. 2018. PMID: 30220640. doi:10.1016/j.ajem.2018.08.072

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。